Navigation Links
Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
Date:7/2/2012

ANAHEIM, Calif., July 2, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today that executive management will present at the JMP Securities Healthcare Conference in New York on July 13, 2012 at 8:00 a.m. PT / 11:00 a.m. ET.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently preparing to launch a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
2. Pharmaceuticals: Global Industry Almanac, MarketLine
3. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
4. Nouveau Life Pharmaceuticals (NOUV) to Launch Affiliate Sales Program
5. Trading Of Onyx Pharmaceuticals Common Stock Halted
6. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
7. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
8. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
9. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
10. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
11. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 11, 2019 , ... HOLLOWAY AMERICA, a leading manufacturer ... beverage to pharma and chemical, recently announced it will showcase its problem-solving vessels and ... , HOLLOWAY AMERICA’s first stop will be at ISPE San Diego’s 27th Life ...
(Date:9/11/2019)... ... 2019 , ... Pivot Point Consulting is excited to announce ... Partnerships team. Maris brings two decades of experience with Cerner—leading both sales ... as a Technical Implementation Leader representing the Technical Engagement Leader community. , Pivot ...
(Date:9/9/2019)... , ... September 09, 2019 , ... ... Shoreline Periodontics & Dental Implants host the latest course in their Synergy Study ... Mystic, CT and features guest speaker Dr. Peter Barndt. Synergy Study Club brings ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... 11, 2019 , ... The 2019 Minnesota Anatomic Complex Knee ... Mall of America Radisson Blu. Four experts from Twin Cities Orthopedics (TCO), including ... conference, which brings together more than 100 national and international orthopedic surgeons for ...
(Date:9/11/2019)... ... 11, 2019 , ... PatientPay, the leading end-to-end patient payment ... of a patent to reduce the level of effort a medical group must ... visit patient statements. , At the core of “Instant Integration for Installment Payments” ...
(Date:9/11/2019)... ... , ... Women’s Excellence is pleased to welcome Dr. Caela ... skilled Obstetrician/Gynecologist. She approaches patients compassionately and offers comprehensive obstetrical and gynecological ... is comfortable, patient-focused, and that every patient feels her concerns have been fully ...
(Date:9/11/2019)... ... September 11, 2019 , ... Dimensional Insight®, a data ... at the annual St. Jude Walk/Run Boston. To be held on Saturday, Sept. 28 ... raise a goal of $650,000 for St. Jude Children’s Research Hospital®. , ...
(Date:9/9/2019)... ... September 09, 2019 , ... Cardinal Park Family Dental Care ... and counting. The practice offers family dentistry , laser gum disease treatment, full ... marks the 20th year that Cardinal Park Family Dental Care has provided state-of-the-art, comprehensive ...
Breaking Medicine News(10 mins):